Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Chemoprophylaxis is currently the best available prevention from malaria, but its efficacy is compromised by non-adherence to medication. Here we develop a long-acting injectable formulation of atovaquone solid drug nanoparticles that confers long-lived prophylaxis against Plasmodium berghei ANKA malaria in C57BL/6 mice. Protection is obtained at plasma concentrations above 200 ng ml and is causal, attributable to drug activity against liver stage parasites. Parasites that appear after subtherapeutic doses remain atovaquone-sensitive. Pharmacokinetic-pharmacodynamic analysis indicates protection can translate to humans at clinically achievable and safe drug concentrations, potentially offering protection for at least 1 month after a single administration. These findings support the use of long-acting injectable formulations as a new approach for malaria prophylaxis in travellers and for malaria control in the field.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778127 | PMC |
| http://dx.doi.org/10.1038/s41467-017-02603-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antipsychotic Treatment Approaches in Schizophrenia Spectrum and Other Psychotic Disorders: Prescription Patterns in Eight Different Diagnostic Groups.
J Clin Psychopharmacol
September 2025
LVR Institute for Research and Education, Department of Research, Wilhelm-Griesinger-Strasse 23.
Background: The objective of this study was to characterize real-world prescription patterns of antipsychotic drugs in patients with various psychiatric disorders with psychotic features.
Method: We analyzed the discharge prescription plans of 59,962 cases with the main diagnoses schizophrenia, schizoaffective disorder, acute transient psychotic disorder, delusional disorder, psychotic bipolar disorder, psychotic depression, organic delusional disorder or substance-induced psychosis. We analyzed the overall use, pharmacological subgroups, the use of long-acting injectable (LAI) formulations, and the frequency of prescription of the singular antipsychotic drugs.
Oral pre-exposure prophylaxis (PrEP) denotes an effective strategy to reduce the risk of HIV infection. However, many individuals encounter difficulties adhering to the once-daily regimen, which highlights the need for a broader portfolio of PrEP options. The novel HIV capsid inhibitor lenacapavir (LEN), when injected every six month, has shown potential in the recently completed clinical trials.
View Article and Find Full Text PDFObjective: Understanding alignment of contraceptive preferences and method selection among women living with HIV (WLWH) may improve contraceptive counseling. We examined whether method attribute preferences aligned with method attributes used among WLWH, and identified preference clusters.
Study Design: We used baseline data from WLWH enrolled in a cluster randomized controlled trial of a reproductive health counseling intervention in Kenya.
Local Delivery of Non-opioid Analgesic Microparticles to Modulate Post-surgical Pain.
Pharm Res
September 2025
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
Purpose: Postsurgical pain (PSP) is a common complication in surgical patients that can progress to chronic pain and opioid dependence. Current analgesics, including opioids and non-opioid agents, are limited by short durations of action and adverse effects. This study reports the development and evaluation of extended-release bupivacaine microparticles (BuMPs) designed to provide sustained local analgesia and improve post-surgical pain management.
View Article and Find Full Text PDFMulticenter Bioavailability Study of Long-Acting Paliperidone in Patients With Schizophrenia or Schizoaffective Disorder.
J Clin Psychopharmacol
September 2025
Department of Operations, Clinical Research Unit, Adium S.A., São Paulo, São Paulo,Brazil.
Purpose/background: Schizophrenia is often associated with nonadherence to oral antipsychotic therapy, which increases the risk of relapse, hospitalization, and higher health care costs. To overcome this challenge, long-acting injectable (LAI) antipsychotics, such as paliperidone palmitate, offer a solution by reducing relapse rates. Also, the bioequivalent formulations can enhance treatment accessibility while maintaining efficacy and safety.
View Article and Find Full Text PDF